Prevalence of Rifampicin Resistance Tuberculosis in Newly Diagnosed and Previously Treated Pulmonary Tuberculosis Patients Attending the Department of Pulmonary Medicine , Muzaffarnagar Medical College, Muzaffarnagar
DOI:
https://doi.org/10.21276/zqz9wp48Keywords:
Rifampicin resistance, MDR –tuberculosis, Gene Xpert, Muzaffarnagar Medical CollegeAbstract
Background: Multidrug-resistant tuberculosis (MDR-TB) prevalence is increasing throughout the world. Although, most important risk factor for development of MDR-TB is inadequate and irregular previous treatment for tuberculosis, but newly treated patients are also at risk due to either spontaneous mutations or transmission of drug-resistant strains. The conventional tuberculosis drug susceptibility tests are sensitive and specific but they are not rapid. Newer molecular methods help in rapid diagnosis. GeneXpert MTB/RIF is a rapid method to detect MTB and rifampicin resistance. Rifampicin resistance is an initial indicator of multidrug resistance. We have tried to ascertain the prevalence of Rifampicin resistance in newly diagnosed and previously treated pulmonary tuberculosis patients.
Methods: This study was a prospective cross sectional study that involved all newly diagnosed and previously treated pulmonary tuberculosis patients attending the Department of Pulmonary Medicine, Muzaffarnagar Medical College, Muzaffarnagar from January 2018 to Dec 2018. In the District Hospital, Muzaffarnagar,the sputum specimens were sent for GeneXpert MTB/RIF .On the basis of the result, the patients were labelled as Rifampicin resistance.
Results: A total no of 118 sputum samples were sent to District Hospital,Muzaffarnagar for GeneXpert MTB/RIF . Among these 118 patients, 102 patients were newly diagnosed pulmonary tuberculosis and 16 patients were previously treated pulmonary tuberculosis . Prevalence of Rifampicin resistance TB was found to be 0.98 % among newly diagnosed pulmonary tuberculosis, and 25 % among previously treated pulmonary tuberculosis patients.
Conclusion: In conclusion, our results showed that the prevalence of Rifampicin resistance TB was high in previously treated pulmonary tuberculosis patient in comparison to newly diagnosed pulmonary tuberculosis patient. Proper administration of first line drugs for susceptible cases is most efficient method in preventing drug resistance.
Downloads
References
Faustini A, Hall A, Perucci C. Risk factors for multi-drug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61 : 158-63.
Sharma SK, Mohan A. Multidrug-resistant tuberculosis - a menace that threatens to destabilize tuberculosis control. Chest 2006; 130 ; 261-72.
Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res. 2004;120:377–86.
Snider DE, Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis. 1985;132:125–
B Mahadev, P Kumar, SP Agarwal, LS Chauhan, N Srikantaramu.
Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tuberc 2005: 52 (1); 5-10.
CN Paramasivan, P Venkataraman, V Chandrasekaran, S Bhat, PR Narayanan. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002: 6 (6); 479-484.
Jain A, Diwakar P, Singh U. Declining trend of resistance to first-line anti- tubercular drugs in clinical isolates of Mycobacterium tuberculosis in a tertiary care north Indian hospital after implementation of revised national tuberculosis control programme. Indian J Med Microbiol. 2014;32:430– 3.
TB India 2012, Annual Status Report Government of India. 2012. [Last accessed on 2015 Jul 12]. Available from: http://www.tbcindia.com .
Jain A, Diwakar P, Singh U. Declining trend of resistance to first-line anti- tubercular drugs in clinical isolates of Mycobacterium tuberculosis in a tertiary care North Indian hospital after implementation of revised national tuberculosis control programme. Indian J Med Microbiol. 2014;32:430–3.
Singhal R, Myneedu VP, Arora J, Singh N, Bhalla M, Verma A, et al. Early detection of multi-drug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoType
MTBDRplus assay. Indian J Med Microbiol. 2015;33(Suppl (1)):46–52. 11. Desikan P, Chauhan DS, Sharma P, Panwalkar N, Yadav P, Ohri BS. Clonal diversity and drug resistance in Mycobacterium tuberculosis isolated from extra-pulmonary samples in central India – A pilot study. Indian J Med Microbiol. 2014;32:434–7.
Jain NK, Chopra KK, Prasad G. Initial and acquired INH and rifampicin resistant to Mycobacterium tuberculosis and its implication for treatment.
Indian J Tuberc 1992; 39: 180- 186.
Trivedi SS, Desai SC. Primary Anti tuberculosis drug resistance and acquired Rifampicin resistance in Gujarat -India. Tubercle 1988; 69:3742.
Shah AR, Agarwal SK, Shah KV. Study of drug resistance in previously treated tuberculosis patients in Gujrat, India. Int J Tuberc Lung Dis 2002;6, 1098–1101.
Malhotra B, Pathak S, Vyas L, Katoch VM, Srivastava K, Chauhan DS et al. Drug susceptibility profiles of mycobacterium tuberculosis isolates at Jaipur. Indian J Med Microbiol 2002; 20(2): 76-78.
Gupta A, Nagaraja MR, Kumari P, Singh G, Raman R, Singh SK, et al. Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India. Indian J Med Microbiol. 2014;32:270–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.
